Policy Reforms in the Indian Pharmaceutical Sector Since 1994: Impact on Exports and Imports

Joseph, Reji K.

doi:10.2139/ssrn.2049286

Cited by 2 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both the above policy changes, it was feared, would hinder pharmaceutical exports from India. On the other hand, it was also expected that the cost advantage of production in India, compliance with good manufacturing practices and the expertise in reverse engineering, would make Indian firms explore new opportunities in the low-volume high-price regulated markets while maintaining the low-price high-volume markets in Asia, Africa and Latin America (Grace, 2004; Joseph, 2012). Contrary to these expectations, it has been observed that there has been remarkable growth in India pharmaceutical exports particularly after 2000 (Chaudhuri, 2005; Dhar & Gopakumar, 2008).…”

Section: A Short Overview Of the Pharmaceutical Industry In Indiamentioning

confidence: 99%

“…Particularly noteworthy was the large investments in research and development made by most major firms. This has helped the industry produce more effective generics which were marketed in the regulated markets of both US and Europe (Joseph, 2012).…”

Section: A Short Overview Of the Pharmaceutical Industry In Indiamentioning

confidence: 99%

“…In general, pharmaceutical products are classified into ‘formulations’ (dosage form) and ‘bulk drugs’ (active pharmaceutical ingredients or APIs). 2 SITC does not use the terms ‘formulations’ and ‘bulk’ explicitly, but classifies pharmaceutical products into two groups—code 541 ‘medicinal and pharmaceutical products, other than medicaments of group 542’ representing bulk drugs and code 542 ‘medicaments (including veterinary medicaments)’ representing formulations (Joseph, 2012).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Why Pharmaceutical Exports from India to Europe Grew During Economic Crisis?

Bose

2017

Management and Labour Studies

View full text Add to dashboard Cite

This article looks into the export trends of pharmaceuticals from India to selected destinations in Europe during the time period 2005–2014. Ten countries of Europe have been selected and divided into two groups—those that are more affected by the crisis beginning in 2008, and those that are less affected. The first group maintained a negative growth rate of GDP more consistently than the second group during the period of study. We found that India’s pharmaceutical exports to European countries, which are relatively more affected by economic crisis, in the time period of study, have increased despite falling income and falling per capita pharmaceutical expenditure. This article investigates the reasons for such trends in exports. Health care and pharmaceutical expenditures in the selected European destinations are largely publicly provided and have been subject to cost-containment policies. The austerity measures in Europe, as they were carried out in health care provision, India’s cost advantage in pharmaceuticals and its advantage as a generic producer and exporter are likely positive contributors to this growth.

show abstract

Section: A Short Overview Of the Pharmaceutical Industry In Indiamentioning

confidence: 99%

Section: A Short Overview Of the Pharmaceutical Industry In Indiamentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation